PharmaCyte Biotech reports preliminary FY2021 net loss of $3.6M, cash $2.2M

PharmaCyte Biotech, Inc.

2023-Q1 EPS reported -$0.64

Net loss for FY2021 was approx. $3.6M ($2.45 loss per share) vs. $3.8M ($4.23 loss per share) in FY2020.
Cash on hand as of April 30, 2021 was approx. $2.2M.
Results are preliminary and unaudited, subject to completion of financial closing procedures.

item 8.01

PharmaCyte Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-21-003222

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.